FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit

Related Content

Hamburg Trumpets Potential Rewards Of Quality Improvement For Generic Industry

CDER Taps Genzyme Exec As Deputy Director For Science Operations

GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm

FDA And Generic Drug Quality: Turning Point, Or Precipice?

Generic Bupropion XL Must Be Retested; Teva/Impax 300 mg Withdrawn After Efficacy Concerns

Generic Drugs Gain Status Boost Within CDER

FDA Office Of Generic Drugs Director Has Brand Industry Background

FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution

FDA's Buehler To Join Teva

FDA's Generic Drugs Office Faces Transition As Director Buehler Departs